Refine
Year of publication
Document Type
- Article (324) (remove)
Language
- English (324)
Has Fulltext
- yes (324)
Is part of the Bibliography
- no (324)
Keywords
- Heavy Ion Experiments (18)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (6)
- LHC (5)
- Hadron-Hadron Scattering (4)
- Quark-Gluon Plasma (4)
- ALICE experiment (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- Beauty production (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Jets (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Single electrons (2)
- pp collisions (2)
- 16S rRNA sequencing (1)
- ALICE (1)
- ALICE detector (1)
- Anti-nuclei (1)
- Aquaporins (1)
- BESIII (1)
- Biomarker (1)
- Bipolar disorder (1)
- Branching fractions (1)
- COVID-19 (1)
- Centrality Class (1)
- Centrality Selection (1)
- Collective Flow (1)
- Diagnostic test (1)
- Differential diagnosis (1)
- D⁰ meson (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Fibre/foam sandwich radiator (1)
- GWAS (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronic decays (1)
- Head and neck Cancer (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy flavor production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Human prostate (1)
- Influenza (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Lymphadenopathy (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiplex immunoassay (1)
- NMR spectroscopy (1)
- Neural network (1)
- Parainfluenza (1)
- Particle Correlations and Fluctuations (1)
- Pharmacodynamics (1)
- Pneumonia (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Prostate cancer cell lines (1)
- Proton–proton (1)
- QCD (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Respiratory syncytial virus (1)
- SARS-CoV-2 (1)
- Salivary gland diseases (1)
- Structured reporting (1)
- Superinfection (1)
- Systematic Uncertainty (1)
- TR (1)
- Target validation (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Trigger (1)
- Ultrasonography (1)
- Upper respiratory tract infection (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- accessory proteins (1)
- amino acid PET (1)
- antiepileptic drugs (1)
- artificial intelligence (1)
- cell-free protein synthesis (1)
- dE/dx (1)
- genetic generalized epilepsy (1)
- glioma (1)
- heavy ion experiments (1)
- intrinsically disordered region (1)
- lamotrigine (1)
- levetiracetam (1)
- microbiome (1)
- nonstructural proteins (1)
- pancreatic cancer (1)
- pancreatic surgery (1)
- pharmacoresistance (1)
- postoperative complications (1)
- quark gluon plasma (1)
- spectra (1)
- structural proteins (1)
- treatment-related changes (1)
- tumor progression (1)
- valproic acid (1)
Institute
Highlights
• A panel of 20 biomarkers was identified capable of differentiating BD patients from controls.
• Excellent discrimination between established BD patients and controls.
• Good to excellent discrimination between misdiagnosed BD patients and first onset MDD patients.
• Fair to good discrimination between pre-diagnostic BD patients and controls.
• Study demonstrates the potential utility of a protein biomarker panel as a diagnostic test for BD.
Abstract
Background: Bipolar disorder (BD) is a costly, devastating and life shortening mental disorder that is often misdiagnosed, especially on initial presentation. Misdiagnosis frequently results in ineffective treatment. We investigated the utility of a biomarker panel as a diagnostic test for BD.
Methods and findings: We performed a meta-analysis of eight case-control studies to define a diagnostic biomarker panel for BD. After validating the panel on established BD patients, we applied it to undiagnosed BD patients. We analysed 249 BD, 122 pre-diagnostic BD, 75 pre-diagnostic schizophrenia and 90 first onset major depression disorder (MDD) patients and 371 controls. The biomarker panel was identified using ten-fold cross-validation with lasso regression applied to the 87 analytes available across the meta-analysis studies.
We identified 20 protein analytes with excellent predictive performance [area under the curve (AUC) ⩾ 0.90]. Importantly, the panel had a good predictive performance (AUC 0.84) to differentiate 12 misdiagnosed BD patients from 90 first onset MDD patients, and a fair to good predictive performance (AUC 0.79) to differentiate between 110 pre-diagnostic BD patients and 184 controls. We also demonstrated the disease specificity of the panel.
Conclusions: An early and accurate diagnosis has the potential to delay or even prevent the onset of BD. This study demonstrates the potential utility of a biomarker panel as a diagnostic test for BD.
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia. Here we characterize imatinib as first-in-class allosteric FXR modulator and report the development of an optimized descendant that markedly promotes agonist induced FXR activation in a reporter gene assay and FXR target gene expression in HepG2 cells. Differential effects of imatinib on agonist-induced bile salt export protein and small heterodimer partner expression suggest that allosteric FXR modulation could open a new avenue to gene-selective FXR modulators.
Using a data sample of e+e− collision data corresponding to an integrated luminosity of 2.93 fb−1 collected with the BESIII detector at a center-of-mass energy of s=3.773GeV, we search for the singly Cabibbo-suppressed decays D0→π0π0π0, π0π0η, π0ηη and ηηη using the double tag method. The absolute branching fractions are measured to be B(D0→π0π0π0)=(2.0±0.4±0.3)×10−4, B(D0→π0π0η)=(3.8±1.1±0.7)×10−4 and B(D0→π0ηη)=(7.3±1.6±1.5)×10−4 with the statistical significances of 4.8σ, 3.8σ and 5.5σ, respectively, where the first uncertainties are statistical and the second ones systematic. No significant signal of D0→ηηη is found, and the upper limit on its decay branching fraction is set to be B(D0→ηηη)<1.3×10−4 at the 90% confidence level.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.